Latest Content

Findings from CRISPR-edited stem cell–derived islets suggest SMOC1 functions as a physiological stabilizer of NKX6.1-positive β-cell identity.

This letter addresses a letter about the study, "The Relationship Between Preventive Dental Care and Overall Medical Expenditures," with the letter detailing why quasi-experimental studies should be used to address bias from unobserved factors.

Two studies identify molecular targets that could help preserve insulin-producing cell function.

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.

FDA clears hands-free on-body injector for isatuximab in multiple myeloma, cutting treatment time and reactions while matching IV efficacy.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A study finds that 1- and 3-month dual antiplatelet therapy reduces bleeding vs standard regimens in patients at high bleeding risk.

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

Explore the biggest FDA PDUFA decisions expected in 2026, including gedatolisib, iberdomide, zidesamtinib, bepirovirsen, and anito-cel.